Clínica Alemana

Running trials

• Recruiting

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

  NCT07027306· AO Foundation, AO Spine· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study

  NCT06839300· AO Foundation, AO Spine· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  NCT07011745· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Genmab· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

  NCT06052059· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  NCT05947851· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05502237· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

  NCT05458297· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  NCT04994717· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

  NCT04544449· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  EULAT Eradicate GBC

  NCT06192719· Centre Paul Strauss· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Follicular lymphoma2 recruiting
• Multiple myeloma2 recruiting
• Alzheimer disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Spinal cord injury1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Feasibility of Using Immersive Virtual Functional Rehabilitation for Recovery of Upper Extremity Function in Patients With Early-stage Stroke: a Pilot Study

  NCT07086365· Clinica Alemana de Santiago· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

  NCT05144841· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

  NCT03734640· Craig Anderson· Source

• Completed

  Validation of Serum Metabolite Differences in Patients With Gallstones and Gallbladder Cancer

  NCT07744477· Centre Paul Strauss· Source

• Completed

  Validation of Differential Serum Levels for Five Minerals in South American Gallstone Patients With and Without Gallbladder Cancer

  NCT07642817· Centre Paul Strauss· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source